Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 15/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13001015 | 1.00 | GRIN2B (0.44) | GRIN2BNPSR1GAANPC1ALDH1A1 | |
| SCHEMBL3393535 | 0.82 | GRIN2B (0.46) | GRIN2BNPSR1GAANPC1ALDH1A1 | |
| SCHEMBL13001013 | 0.82 | GRIN2B (0.46) | GRIN2BNPSR1GAANPC1ALDH1A1 | |
| SCHEMBL13001025 | 0.82 | GRIN2B (0.46) | GRIN2BNPSR1GAANPC1ALDH1A1 | |
| SCHEMBL3397597 | 0.82 | GRIN2B (0.46) | GRIN2BNPSR1GAANPC1ALDH1A1 | |
| SCHEMBL13001027 | 0.80 | GRIN2B (0.41) | GRIN2BNPSR1GAANPC1ALDH1A1 | |
| SCHEMBL3397560 | 0.80 | GRIN2B (0.44) | GRIN2BNPSR1GAANPC1ALDH1A1 | |
| SCHEMBL13001019 | 0.79 | GRIN2B (0.44) | GRIN2BNPSR1GAANPC1ALDH1A1 | |
| SCHEMBL3393544 | 0.79 | GRIN2B (0.44) | GRIN2BNPSR1GAANPC1ALDH1A1 | |
| SCHEMBL13001095 | 0.78 | DPP4 (0.38) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2246347-B1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2016-09-28 | — | — | EP | disclosed |
| US-8415349-B2 | Dicycloazaalkane derivatives, preparation processes and medical uses thereof | Jiangsu Hansoh Pharmaceuticals Co., Ltd. (CN) | 2013-04-09 | — | — | US | disclosed |
| US-20130012705-A1 | DICYCLOAZAALKANE DERIVATIVES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2013-01-10 | — | — | US | disclosed |
| US-8304411-B2 | Dicycloazaalkane derivates, preparation processes and medical uses thereof | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2012-11-06 | — | — | US | disclosed |
| US-20100311747-A1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO. LTD. (CN) | 2010-12-09 | — | — | US | disclosed |
| EP-2246347-A1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2010-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012705-A1 | DICYCLOAZAALKANE DERIVATIVES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | DPP4, DPP8, DPP7 | GRIN2B 2970/4885NPSR1 2649/4885GAA 62/4885 |
| US-20100311747-A1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | DPP4, DPP8, DPP7 | GRIN2B 2680/4885NPSR1 2471/4885GAA 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.